{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:24:54Z","timestamp":1784762694421,"version":"3.55.0"},"reference-count":126,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Pseudomonas aeruginosa, a multidrug-resistant pathogen, significantly impacts patients with chronic respiratory conditions like cystic fibrosis (CF) and non-CF chronic suppurative lung disease (CSLD), contributing to progressive lung damage and poor clinical outcomes. This bacterium thrives in the airway environments of individuals with impaired mucociliary clearance, leading to persistent infections and increased morbidity and mortality. Despite advancements in management of these conditions, treatment failure remains common, emphasising the need for alternative or adjunctive treatment strategies. Bacteriophage therapy, an emerging approach utilising viruses that specifically target bacteria, offers a potential solution to combat P. aeruginosa infections resistant to conventional antibiotics. This review examines the prevalence and disease burden of P. aeruginosa in CF and CSLD, explores the mechanisms behind antibiotic resistance, the promising role of bacteriophage therapy and clinical trials in this sphere.<\/jats:p>","DOI":"10.3390\/antibiotics14050427","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T10:40:48Z","timestamp":1745404848000},"page":"427","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Overcoming Pseudomonas aeruginosa in Chronic Suppurative Lung Disease: Prevalence, Treatment Challenges, and the Promise of Bacteriophage Therapy"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6162-6483","authenticated-orcid":false,"given":"Jagdev","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, The Children\u2019s Hospital at Westmead, Sydney, NSW 2145, Australia"},{"name":"Faculty of Medicine, University of Sydney, Sydney, NSW 2145, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Solomon","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hospital for Sick Children, Toronto, ON M5G 1X8, Canada"},{"name":"Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Iredell","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Sydney, Sydney, NSW 2145, Australia"},{"name":"Westmead Institute of Medical Research, Sydney, NSW 2145, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiran","family":"Selvadurai","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, The Children\u2019s Hospital at Westmead, Sydney, NSW 2145, Australia"},{"name":"Faculty of Medicine, University of Sydney, Sydney, NSW 2145, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/cid\/ciy378","article-title":"Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1080\/17476348.2021.1906225","article-title":"Pseudomonas aeruginosa in bronchiectasis: Infection, inflammation, and therapies","volume":"15","author":"Vidaillac","year":"2021","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Faure, E., Kwong, K., and Nguyen, D. (2018). Pseudomonas aeruginosa in Chronic Lung Infections: How to Adapt Within the Host?. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02416"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.biotechadv.2018.11.013","article-title":"Antibiotic resistance in Pseudomonas aeruginosa: Mechanisms and alternative therapeutic strategies","volume":"37","author":"Pang","year":"2019","journal-title":"Biotechnol. Adv."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Cha\u00efbi, K., Jaureguy, F., Do Rego, H., Ruiz, P., Mory, C., El Helali, N., Mrabet, S., Mizrahi, A., Zahar, J.-R., and Pilmis, B. (2023). What to Do with the New Antibiotics?. Antibiotics, 12.","DOI":"10.3390\/antibiotics12040654"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Br\u00fcssow, H. (2024). The antibiotic resistance crisis and the development of new antibiotics. Microb. Biotechnol., 17.","DOI":"10.1111\/1751-7915.14510"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1001\/jama.2023.8120","article-title":"Cystic fibrosis: A review","volume":"329","author":"Ong","year":"2023","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2301241","DOI":"10.1183\/13993003.01241-2023","article-title":"Cystic fibrosis in Europe: Improved lung function and longevity\u2014Reasons for cautious optimism, but challenges remain","volume":"63","author":"Kerem","year":"2024","journal-title":"Eur. Respir. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jcf.2023.09.011","article-title":"Longitudinal bacterial prevalence in cystic fibrosis airways: Fact and artifact","volume":"23","author":"VanDevanter","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Singh, J., Hunt, S., Simonds, S., Boyton, C., Middleton, A., Elias, M., Towns, S., Pandit, C., Robinson, P., and Fitzgerald, D.A. (2024). The changing epidemiology of pulmonary infection in children and adolescents with cystic fibrosis: An 18-year experience. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-59658-4"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jcf.2023.10.014","article-title":"A birth cohort approach to understanding cystic fibrosis lung infections","volume":"23","author":"Fischer","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jcf.2021.09.017","article-title":"Risk factors for Pseudomonas aeruginosa airway infection and lung function decline in children with cystic fibrosis","volume":"21","author":"Ruffin","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jcf.2017.10.008","article-title":"Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosis","volume":"17","author":"Heltshe","year":"2018","journal-title":"J. Cyst. Fibros."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jcf.2020.10.008","article-title":"Factors influencing the acquisition and eradication of early Pseudomonas aeruginosa infection in cystic fibrosis","volume":"20","author":"Jackson","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1378\/chest.11-0917","article-title":"Incidence and Risk Factors for Pulmonary Exacerbation Treatment Failures in Patients with Cystic Fibrosis Chronically Infected with Pseudomonas aeruginosa","volume":"141","author":"Parkins","year":"2012","journal-title":"Chest"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/ppul.21117","article-title":"Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis","volume":"45","author":"Sanders","year":"2010","journal-title":"Pediatr. Pulmonol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.23736\/S2724-5276.23.07221-X","article-title":"Factors influencing treatment response of pulmonary exacerbation in children with cystic fibrosis","volume":"76","author":"Singh","year":"2024","journal-title":"Minerva Pediatr."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"105461","DOI":"10.1016\/j.micpath.2022.105461","article-title":"Prevalence of antibiotic resistance of Pseudomonas aeruginosa in cystic fibrosis infection: A systematic review and meta-analysis","volume":"165","author":"Bonyadi","year":"2022","journal-title":"Microb. Pathog."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1183\/20734735.0178-2019","article-title":"Protracted bacterial bronchitis is a precursor for bronchiectasis in children: Myth or maxim?","volume":"15","author":"Chang","year":"2019","journal-title":"Breathe"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/resp.14479","article-title":"Thoracic Society of Australia and New Zealand (TSANZ) position statement on chronic suppurative lung disease and bronchiectasis in children, adolescents and adults in Australia and New Zealand","volume":"28","author":"Chang","year":"2023","journal-title":"Respirology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1183\/13993003.01033-2015","article-title":"Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: A population-based cohort study","volume":"47","author":"Quint","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_23","unstructured":"Telfar Barnard, L., and Zhang, J. (2021). The Impact of Respiratory Disease in New Zealand: 2020 Update, Asthma and Respiratory Foundation NZ."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/1479972317709649","article-title":"Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013","volume":"14","author":"Weycker","year":"2017","journal-title":"Chronic Respir. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"McCallum, G.B., and Binks, M.J. (2017). The Epidemiology of Chronic Suppurative Lung Disease and Bronchiectasis in Children and Adolescents. Front. Pediatr., 5.","DOI":"10.3389\/fped.2017.00027"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/ppul.23952","article-title":"Comparison of bronchoscopy and bronchoalveolar lavage findings in three types of suppurative lung disease","volume":"53","author":"Chang","year":"2018","journal-title":"Pediatr. Pulmonol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2147\/COPD.S150250","article-title":"Antibiotic-resistant Pseudomonas aeruginosa infection in patients with bronchiectasis: Prevalence, risk factors and prognostic implications","volume":"13","author":"Gao","year":"2018","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1378\/chest.07-0490","article-title":"Factors Associated With Lung Function Decline in Adult Patients With Stable Non-Cystic Fibrosis Bronchiectasis","volume":"132","author":"Soriano","year":"2007","journal-title":"Chest"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12931-023-02391-9","article-title":"Pseudomonas aeruginosa isolation is an important predictor for recurrent hemoptysis after bronchial artery embolization in patients with idiopathic bronchiectasis: A multicenter cohort study","volume":"24","author":"Wang","year":"2023","journal-title":"Respir. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.rmed.2019.06.012","article-title":"Mucoid Pseudomonas aeruginosa alters sputum viscoelasticity in patients with non-cystic fibrosis bronchiectasis","volume":"154","author":"Scioscia","year":"2019","journal-title":"Respir. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"230178","DOI":"10.1183\/16000617.0178-2023","article-title":"Eradication treatment for Pseudomonas aeruginosa infection in adults with bronchiectasis: A systematic review and meta-analysis","volume":"33","author":"Shteinberg","year":"2024","journal-title":"Eur. Respir. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/15412555.2021.1884214","article-title":"Risk Factors and Relation with Mortality of a New Acquisition and Persistence of Pseudomonas aeruginosa in COPD Patients","volume":"18","author":"Faner","year":"2021","journal-title":"COPD J. Chronic Obstr. Pulm. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000331224","article-title":"Pseudomonas aeruginosa and mortality after hospital admission for chronic obstructive pulmonary disease","volume":"84","author":"Almagro","year":"2012","journal-title":"Respiration"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cmi.2019.06.011","article-title":"Pseudomonas aeruginosa and risk of death and exacerbations in patients with chronic obstructive pulmonary disease: An observational cohort study of 22 053 patients","volume":"26","author":"Ingebrigtsen","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"ofz546","DOI":"10.1093\/ofid\/ofz546","article-title":"Impact of Pseudomonas aeruginosa Isolation on Mortality and Outcomes in an Outpatient Chronic Obstructive Pulmonary Disease Cohort","volume":"7","author":"Jacobs","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Giovagnorio, F., De Vito, A., Madeddu, G., Parisi, S.G., and Geremia, N. (2023). Resistance in Pseudomonas aeruginosa: A Narrative Review of Antibiogram Interpretation and Emerging Treatments. Antibiotics, 12.","DOI":"10.3390\/antibiotics12111621"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Sindeldecker, D., and Stoodley, P. (2021). The many antibiotic resistance and tolerance strategies of Pseudomonas aeruginosa. Biofilm, 3.","DOI":"10.1016\/j.bioflm.2021.100056"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Moussouni, M., Berry, L., Sipka, T., Nguyen-Chi, M., and Blanc-Potard, A.-B. (2021). Pseudomonas aeruginosa OprF plays a role in resistance to macrophage clearance during acute infection. Sci. Rep., 11.","DOI":"10.1038\/s41598-020-79678-0"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Dreier, J., and Ruggerone, P. (2015). Interaction of antibacterial compounds with RND efflux pumps in Pseudomonas aeruginosa. Front. Microbiol., 6.","DOI":"10.3389\/fmicb.2015.00660"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1038\/s41467-024-46938-w","article-title":"Mutations in the efflux pump regulator MexZ shift tissue colonization by Pseudomonas aeruginosa to a state of antibiotic tolerance","volume":"15","author":"Laborda","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40121-022-00591-2","article-title":"Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa","volume":"11","author":"Holger","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/22221751.2022.2048972","article-title":"Carbapenemase-producing Pseudomonas aeruginosa\u2014An emerging challenge","volume":"11","author":"Tenover","year":"2022","journal-title":"Emerg. Microbes Infect."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Munita, J.M., and Arias, C.A. (2016). Mechanisms of Antibiotic Resistance. Virulence Mechanisms of Bacterial Pathogens, ASM Press.","DOI":"10.1128\/9781555819286.ch17"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41579-020-00477-5","article-title":"Pseudomonas aeruginosa adaptation and evolution in patients with cystic fibrosis","volume":"19","author":"Rossi","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_45","first-page":"000513","article-title":"From genotype to phenotype: Adaptations of Pseudomonas aeruginosa to the cystic fibrosis environment","volume":"7","author":"Camus","year":"2021","journal-title":"Microb. Genom."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1126\/science.288.5469.1251","article-title":"High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection","volume":"288","author":"Oliver","year":"2000","journal-title":"Science"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.02142-19","article-title":"Hypermutator Pseudomonas aeruginosa Exploits Multiple Genetic Pathways to Develop Multidrug Resistance during Long-Term Infections in the Airways of Cystic Fibrosis Patients","volume":"64","author":"Colque","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/ng.3148","article-title":"Convergent evolution and adaptation of Pseudomonas aeruginosa within patients with cystic fibrosis","volume":"47","author":"Marvig","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Rees, V.E., Lucas, D.S.D., L\u00f3pez-Causap\u00e9, C., Huang, Y., Kotsimbos, T., Bulitta, J.B., Rees, M.C., Barugahare, A., Peleg, A.Y., and Nation, R.L. (2019). Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.02538-18"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Michaelis, C., and Grohmann, E. (2023). Horizontal Gene Transfer of Antibiotic Resistance Genes in Biofilms. Antibiotics, 12.","DOI":"10.3390\/antibiotics12020328"},{"key":"ref_51","first-page":"253","article-title":"Adaptive resistance to antibiotics in bacteria: A systems biology perspective","volume":"8","author":"Aldana","year":"2016","journal-title":"Syst. Biol. Med."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Guillaume, O., Butnarasu, C., Visentin, S., and Reimhult, E. (2022). Interplay between biofilm microenvironment and pathogenicity of Pseudomonas aeruginosa in cystic fibrosis lung chronic infection. Biofilm, 4.","DOI":"10.1016\/j.bioflm.2022.100089"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e0126922","DOI":"10.1128\/spectrum.01269-22","article-title":"Evidence for Complex Interplay between Quorum Sensing and Antibiotic Resistance in Pseudomonas aeruginosa","volume":"10","author":"Sikdar","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrmicro3076","article-title":"A problem of persistence: Still more questions than answers?","volume":"11","author":"Balaban","year":"2013","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Patel, H., Buchad, H., and Gajjar, D. (2022). Pseudomonas aeruginosa persister cell formation upon antibiotic exposure in planktonic and biofilm state. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-20323-3"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.cell.2014.02.050","article-title":"Molecular mechanisms underlying bacterial persisters","volume":"157","author":"Maisonneuve","year":"2014","journal-title":"Cell"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4161\/bact.1.1.14942","article-title":"Phages in nature","volume":"1","author":"Clokie","year":"2011","journal-title":"Bacteriophage"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Altamirano, F.L.G., and Barr, J.J. (2019). Phage Therapy in the Postantibiotic Era. Clin. Microbiol. Rev., 32.","DOI":"10.1128\/CMR.00066-18"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.jiph.2021.10.020","article-title":"Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects","volume":"14","author":"Uddin","year":"2021","journal-title":"J. Infect. Public Health"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4052","DOI":"10.1038\/s41467-023-39756-z","article-title":"High-resolution cryo-EM structure of the Pseudomonas bacteriophage E217","volume":"14","author":"Li","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e28281","DOI":"10.4161\/bact.28281","article-title":"Molecular architecture of tailed double-stranded DNA phages","volume":"4","author":"Fokine","year":"2014","journal-title":"Bacteriophage"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"McCutcheon, J.G., Peters, D.L., and Dennis, J.J. (2018). Identification and Characterization of Type IV Pili as the Cellular Receptor of Broad Host Range Stenotrophomonas maltophilia Bacteriophages DLP1 and DLP2. Viruses, 10.","DOI":"10.3390\/v10060338"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e00744-13","DOI":"10.1128\/genomeA.00744-13","article-title":"Complete genome sequence of Pseudomonas aeruginosa podophage MPK7, which requires type IV pili for infection","volume":"1","author":"Bae","year":"2013","journal-title":"Genome Announc."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Fernandes, S., and S\u00e3o-Jos\u00e9, C. (2018). Enzymes and Mechanisms Employed by Tailed Bacteriophages to Breach the Bacterial Cell Barriers. Viruses, 10.","DOI":"10.3390\/v10080396"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e1062590","DOI":"10.1080\/21597081.2015.1062590","article-title":"Antimicrobial bacteriophage-derived proteins and therapeutic applications","volume":"5","author":"Roach","year":"2015","journal-title":"Bacteriophage"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"13487","DOI":"10.1038\/s41598-019-50030-5","article-title":"Identification and characterization of phage protein and its activity against two strains of multidrug-resistant Pseudomonas aeruginosa","volume":"9","author":"Brzozowska","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Chan, B.K., Sistrom, M., Wertz, J.E., Kortright, K.E., Narayan, D., and Turner, P.E. (2016). Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci. Rep., 6.","DOI":"10.1038\/srep26717"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1038\/s44318-024-00195-1","article-title":"Structure and replication of Pseudomonas aeruginosa phage JBD30","volume":"43","author":"Plevka","year":"2024","journal-title":"EMBO J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e12435","DOI":"10.15252\/emmm.202012435","article-title":"Biological foundations of successful bacteriophage therapy","volume":"14","author":"Venturini","year":"2022","journal-title":"EMBO Mol. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0065-2164(10)70007-1","article-title":"Bacteriophage host range and bacterial resistance","volume":"70","author":"Hyman","year":"2010","journal-title":"Adv. Appl. Microbiol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nrmicro2315","article-title":"Bacteriophage resistance mechanisms","volume":"8","author":"Labrie","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/emph\/eoy005","article-title":"Phage treatment of an aortic graft infected with Pseudomonas aeruginosa","volume":"2018","author":"Chan","year":"2018","journal-title":"Evol. Med. Public Health"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e0021821","DOI":"10.1128\/msystems.00218-21","article-title":"The Future of Bacteriophage Therapy Will Promote Antimicrobial Susceptibility","volume":"6","author":"Barber","year":"2021","journal-title":"mSystems"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Mangalea, M.R., and Duerkop, B.A. (2020). Fitness Trade-Offs Resulting from Bacteriophage Resistance Potentiate Synergistic Antibacterial Strategies. Infect. Immun., 88.","DOI":"10.1128\/IAI.00926-19"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e02914-22","DOI":"10.1128\/spectrum.02914-22","article-title":"Fitness Trade-Offs in Phage Cocktail-Resistant Salmonella enterica Serovar Enteritidis Results in Increased Antibiotic Susceptibility and Reduced Virulence","volume":"10","author":"Gao","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Egido, J.E., Costa, A.R., Aparicio-Maldonado, C., Haas, P.-J., and Brouns, S.J.J. (2021). Mechanisms and clinical importance of bacteriophage resistance. FEMS Microbiol. Rev., 46.","DOI":"10.1093\/femsre\/fuab048"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jtbi.2007.08.007","article-title":"Optimal bacteriophage mutation rates for phage therapy","volume":"249","author":"Kysela","year":"2007","journal-title":"J. Theor. Biol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Nazarov, P.A. (2022). MDR Pumps as Crossroads of Resistance: Antibiotics and Bacteriophages. Antibiotics, 11.","DOI":"10.3390\/antibiotics11060734"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1128\/JCM.37.6.1771-1776.1999","article-title":"The Calgary Biofilm Device: New Technology for Rapid Determination of Antibiotic Susceptibilities of Bacterial Biofilms","volume":"37","author":"Ceri","year":"1999","journal-title":"J. Clin. Microbiol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Schurek, K.N., Breidenstein, E.B., and Hancock, R.E. (2011). Pseudomonas aeruginosa: A persistent pathogen in cystic fibrosis and hospital-associated infections. Antibiotic Discovery and Development, Springer.","DOI":"10.1007\/978-1-4614-1400-1_21"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/NSA.S325594","article-title":"Bacterial Biofilm Destruction: A Focused Review On The Recent Use of Phage-Based Strategies With Other Antibiofilm Agents","volume":"14","author":"Amankwah","year":"2021","journal-title":"Nanotechnol. Sci. Appl."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Ferriol-Gonz\u00e1lez, C., and Domingo-Calap, P. (2020). Phages for Biofilm Removal. Antibiotics, 9.","DOI":"10.3390\/antibiotics9050268"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41467-023-44157-3","article-title":"Phage Paride can kill dormant, antibiotic-tolerant cells of Pseudomonas aeruginosa by direct lytic replication","volume":"15","author":"Maffei","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"6310","DOI":"10.7150\/thno.42573","article-title":"Phage-delivered sensitisation with subsequent antibiotic treatment reveals sustained effect against antimicrobial resistant bacteria","volume":"10","author":"Liu","year":"2020","journal-title":"Theranostics"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/eva.12364","article-title":"Long-term effects of single and combined introductions of antibiotics and bacteriophages on populations of Pseudomonas aeruginosa","volume":"9","author":"Franzon","year":"2016","journal-title":"Evol. Appl."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e02085-18","DOI":"10.1128\/AEM.02085-18","article-title":"Phage-Antibiotic Synergy via Delayed Lysis","volume":"84","author":"Kim","year":"2018","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_87","first-page":"703","article-title":"Synergistic interaction between phage therapy and antibiotics clears Pseudomonas aeruginosa infection in endocarditis and reduces virulence","volume":"215","author":"Oechslin","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e24932","DOI":"10.1002\/jcla.24932","article-title":"Bacteriophages: The promising therapeutic approach for enhancing ciprofloxacin efficacy against bacterial infection","volume":"37","author":"Shariati","year":"2023","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_89","first-page":"e03219","article-title":"Exploiting phage-antibiotic synergies to disrupt Pseudomonas aeruginosa PAO1 biofilms in the context of orthopedic infections","volume":"12","author":"Soir","year":"2024","journal-title":"Microbiol. Spectr."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1007\/s12275-011-1512-4","article-title":"Antibacterial efficacy of lytic Pseudomonas bacteriophage in normal and neutropenic mice models","volume":"49","author":"Tiwari","year":"2011","journal-title":"J. Microbiol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.chom.2017.06.018","article-title":"Synergy between the Host Immune System and Bacteriophage Is Essential for Successful Phage Therapy against an Acute Respiratory Pathogen","volume":"22","author":"Roach","year":"2017","journal-title":"Cell Host Microbe"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2147\/BTT.S381237","article-title":"Phage Therapy: A Different Approach to Fight Bacterial Infections","volume":"16","author":"Hibstu","year":"2022","journal-title":"Biol. Targets Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.4049\/jimmunol.1701745","article-title":"Contribution of the immune response to phage therapy","volume":"200","author":"Krut","year":"2018","journal-title":"J. Immunol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/s41564-024-01705-x","article-title":"Personalized bacteriophage therapy outcomes for 100 consecutive cases: A multicentre, multinational, retrospective observational study","volume":"9","author":"Pirnay","year":"2024","journal-title":"Nat. Microbiol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e065401","DOI":"10.1136\/bmjopen-2022-065401","article-title":"Standardised treatment and monitoring protocol to assess safety and tolerability of bacteriophage therapy for adult and paediatric patients (STAMP study): Protocol for an open-label, single-arm trial","volume":"12","author":"Khatami","year":"2022","journal-title":"BMJ Open"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"ofad221","DOI":"10.1093\/ofid\/ofad221","article-title":"Compassionate Use of Bacteriophages for Failed Persistent Infections During the First 5 Years of the Israeli Phage Therapy Center","volume":"10","author":"Onallah","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_97","unstructured":"Koff, J. (2025, January 01). Cystic Fibrosis Phage Study at YALE (CYPHY), Available online: https:\/\/cdn.clinicaltrials.gov\/large-docs\/41\/NCT04684641\/Prot_SAP_000.pdf."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e001360","DOI":"10.1136\/bmjresp-2022-001360","article-title":"Single-arm, open-labelled, safety and tolerability of intrabronchial and nebulised bacteriophage treatment in children with cystic fibrosis and Pseudomonas aeruginosa","volume":"10","author":"Jagdev","year":"2023","journal-title":"BMJ Open Respir. Res."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"G\u00f3rski, A., Mi\u0119dzybrodzki, R., \u0141obocka, M., G\u0142owacka-Rutkowska, A., Bednarek, A., Borysowski, J., Jo\u0144czyk-Matysiak, E., \u0141usiak-Szelachowska, M., Weber-D\u0105browska, B., and Bagi\u0144ska, N. (2018). Phage Therapy: What Have We Learned?. Viruses, 10.","DOI":"10.3390\/v10060288"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.clinthera.2020.07.014","article-title":"Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?","volume":"42","author":"Luong","year":"2020","journal-title":"Clin. Ther."},{"key":"ref_101","first-page":"A6808","article-title":"Cystic Fibrosis Bacteriophage Study at Yale (CYPHY)","volume":"209","author":"Stanley","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"199442","DOI":"10.1016\/j.virusres.2024.199442","article-title":"Safety and tolerability of bronchoscopic and nebulised administration of bacteriophage","volume":"348","author":"Singh","year":"2024","journal-title":"Virus Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s15010-019-01319-0","article-title":"Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient","volume":"47","author":"Law","year":"2019","journal-title":"Infection"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1038\/s41467-023-39370-z","article-title":"Personalized aerosolised bacteriophage treatment of a chronic lung infection due to multidrug-resistant Pseudomonas aeruginosa","volume":"14","author":"Luscher","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"23247096231188243","DOI":"10.1177\/23247096231188243","article-title":"Bacteriophage therapy for pan-drug-resistant Pseudomonas aeruginosa in two persons with cystic fibrosis","volume":"11","author":"Hahn","year":"2023","journal-title":"J. Investig. Med. High Impact Case Rep."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/1751-7915.14217","article-title":"First-in-human application of double-stranded RNA bacteriophage in the treatment of pulmonary Pseudomonas aeruginosa infection","volume":"16","author":"Li","year":"2023","journal-title":"Microb. Biotechnol."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Abedon, S.T., Danis-Wlodarczyk, K.M., and Wozniak, D.J. (2021). Phage Cocktail Development for Bacteriophage Therapy: Toward Improving Spectrum of Activity Breadth and Depth. Pharmaceuticals, 14.","DOI":"10.3390\/ph14101019"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1080\/03009734.2019.1688433","article-title":"Pharmacological limitations of phage therapy","volume":"124","author":"Nilsson","year":"2019","journal-title":"Upsala J. Med. Sci."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e187996","DOI":"10.1172\/JCI187996","article-title":"Bacteriophage therapy for multidrug-resistant infections: Current technologies and therapeutic approaches","volume":"135","author":"Kim","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Daubie, V., Chalhoub, H., Blasdel, B., Dahma, H., Merabishvili, M., Glonti, T., De Vos, N., Quintens, J., Pirnay, J.P., and Hallin, M. (2022). Determination of phage susceptibility as a clinical diagnostic tool: A routine perspective. Front. Cell. Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.1000721"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Garc\u00eda, R., Latz, S., Romero, J., Higuera, G., Garc\u00eda, K., and Bast\u00edas, R. (2019). Bacteriophage production models: An overview. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.01187"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Jo\u00e3o, J., Lampreia, J., Prazeres, D.M.F., and Azevedo, A.M. (2021). Manufacturing of bacteriophages for therapeutic applications. Biotechnol. Adv., 49.","DOI":"10.1016\/j.biotechadv.2021.107758"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Pirnay, J.-P., Merabishvili, M., Van Raemdonck, H., De Vos, D., and Verbeken, G. (2018). Bacteriophage production in compliance with regulatory requirements. Bacteriophage Therapy: From Lab to Clinical Practice, Springer.","DOI":"10.1007\/978-1-4939-7395-8_18"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1042\/EBC20240013","article-title":"Considerations for prioritising clinical research using bacteriophage","volume":"68","author":"Edwards","year":"2024","journal-title":"Essays Biochem."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Harper, D.R., Abedon, S.T., Burrowes, B.H., and McConville, M.L. (2021). Clinical Trials of Bacteriophage Therapeutics. Bacteriophages: Biology, Technology, Therapy, Springer International Publishing.","DOI":"10.1007\/978-3-319-41986-2"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1111\/ajt.15503","article-title":"Early clinical experience of bacteriophage therapy in 3 lung transplant recipients","volume":"19","author":"Aslam","year":"2019","journal-title":"Am. J. Transplant."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Zalewska-Pi\u0105tek, B. (2023). Phage Therapy\u2014Challenges, Opportunities and Future Prospects. Am. J. Transplant., 16.","DOI":"10.3390\/ph16121638"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Jones, J.D., Trippett, C., Suleman, M., Clokie, M.R., and Clark, J.R. (2023). The future of clinical phage therapy in the United Kingdom. Viruses, 15.","DOI":"10.3390\/v15030721"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e0207121","DOI":"10.1128\/aac.02071-21","article-title":"Considerations for the use of phage therapy in clinical practice","volume":"66","author":"Suh","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.medj.2024.05.017","article-title":"Neutralizing antibodies after nebulized phage therapy in cystic fibrosis patients","volume":"5","author":"Chan","year":"2024","journal-title":"Med"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1038\/s41467-024-47192-w","article-title":"Phage-specific immunity impairs efficacy of bacteriophage targeting Vancomycin Resistant Enterococcus in a murine model","volume":"15","author":"Berkson","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"106467","DOI":"10.1016\/j.micpath.2023.106467","article-title":"Bacteriophage therapy against ESKAPE bacterial pathogens: Current status, strategies, challenges, and future scope","volume":"186","author":"Kulshrestha","year":"2024","journal-title":"Microb. Pathog."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s41579-024-01054-w","article-title":"ESKAPE pathogens: Antimicrobial resistance, epidemiology, clinical impact and therapeutics","volume":"22","author":"Miller","year":"2024","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Lorusso, A.B., Carrara, J.A., Barroso, C.D.N., Tuon, F.F., and Faoro, H. (2022). Role of efflux pumps on antimicrobial resistance in Pseudomonas aeruginosa. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232415779"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Yang, Q., Le, S., Zhu, T., and Wu, N. (2023). Regulations of phage therapy across the world. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1250848"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Chaudhry, W.N., Concepcion-Acevedo, J., Park, T., Andleeb, S., Bull, J.J., and Levin, B.R. (2017). Synergy and order effects of antibiotics and phages in killing Pseudomonas aeruginosa biofilms. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0168615"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/5\/427\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:20:08Z","timestamp":1760030408000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/5\/427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":126,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["antibiotics14050427"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics14050427","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]}}}